Today: 30 April 2026
Browse Category

Health News 8 August 2025 - 16 October 2025

INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility (NASDAQ: IVF) Stock Skyrockets 90% as Fertility Boom Fuels Frenzy

INVO Fertility shares surged 89.6% to $1.43 on Oct. 16, with intraday highs of $2.03 and over 108 million shares traded—far above its 5.5 million share float. The rally follows a $200,000 preferred share sale and a recent SEC filing to register 8.35 million shares for resale. The company remains unprofitable and faces liquidity pressures. Year-to-date, the stock is up 95% but still trades 98% below its 52-week high.
16 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares surged 41% after hours on Oct 14, 2025, to $0.36 following new data on its lead cancer therapy. The stock closed regular trading up 30% at $0.25, with volume spiking to 15 million shares. Market cap reached about $11 million. The company’s REQORSA gene therapy is in Phase 2 trials for lung cancer, with new preclinical data set for release at an upcoming oncology conference.
15 October 2025
···
Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences shares jumped over 250% intraday on Oct. 6, 2025, after the FDA granted Breakthrough Therapy Designation to its lead drug, tralesinidase alfa, for Sanfilippo Syndrome Type B. The stock rose from around $9 to $31. Spruce regained its Nasdaq listing in September following a reverse split. The company reported $16.4 million in cash as of June 30 and remains unprofitable.
6 October 2025
··
‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

The XFG (“Stratus”) COVID variant accounted for about 67% of global sequences by late August 2025, according to WHO. The agency classifies XFG as a Variant Under Monitoring with low added public-health risk. Most cases remain mild in vaccinated people. U.S. CDC reports overall COVID activity is declining, with XFG now dominant in wastewater data.
28 September 2025
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

The FDA approved Leqembi IQLIK, the first at-home injectable Alzheimer’s treatment, enabling weekly self-administered doses. U.S. regulators also cleared Sanofi’s Wayrilz, the first BTK inhibitor for chronic immune thrombocytopenia. Cytokinetics’ aficamten outperformed metoprolol in a Phase 3 heart drug trial. WHO warned Gaza has run out of critical medical supplies amid a spike in Guillain-Barré syndrome cases.
30 August 2025
····
COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

The FDA approved updated COVID-19 boosters from Pfizer and Moderna but restricted them to seniors and high-risk groups, excluding healthy children. Infectious disease experts warned the move could leave millions unprotected. The CDC director was fired after refusing to follow anti-vaccine directives, triggering mass resignations among top officials.
29 August 2025
·
Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

AbbVie agreed to acquire Gilgamesh Pharmaceuticals’ experimental psychedelic depression drug for up to $1.2 billion, planning to advance it to Phase 3 trials. Japan’s Terumo will buy UK-based OrganOx for $1.5 billion, gaining organ preservation technology. LB Pharma filed for a $100 million IPO, the first biotech IPO in six months. Arnatar Therapeutics raised $52 million to develop RNA therapy for Alagille syndrome.
26 August 2025
··
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

CSL will cut up to 15% of its workforce and spin off its vaccine unit, targeting $500–550 million in annual savings. Medtronic agreed to add two board members and form new committees after Elliott Investment Management took a major stake. Merck KGaA and Skyhawk Therapeutics announced a neurological drug pact worth up to $2 billion. Pfizer, Bristol Myers Squibb, and Regeneron reported improved Q2 2025 earnings.
20 August 2025
·····
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s melanoma vaccine Cylembia plus Merck’s Keytruda missed statistical significance in Phase 3, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. The FDA approved PharmaTher’s ketamine (KETARx) for anesthesia and pain. A dengue outbreak in Pacific Island nations has infected over 16,500 and killed 17 in 2025, with Fiji, Samoa, and Tonga hardest hit.
12 August 2025
Breakthrough Cures, Big Pharma Shake-Ups & Health Policy Bombshells – Biotech/Health News (Aug 7–8, 2025)

Breakthrough Cures, Big Pharma Shake-Ups & Health Policy Bombshells – Biotech/Health News (Aug 7–8, 2025)

Scripps Research announced T7-ORACLE, a platform that accelerates protein evolution 100,000-fold in living cells, published Aug. 7 in Science. Harvard scientists reported in Nature that lithium reversed memory loss in Alzheimer’s mouse models. The FDA launched “PreCheck” to speed approval of U.S. drug plants. Regulators imposed new safety warnings on Bluebird Bio’s gene therapy Skysona.
8 August 2025
1 2 3

Stock Market Today

  • Morgan Stanley Launches First Major Wall Street Spot Bitcoin ETF
    April 30, 2026, 11:57 AM EDT. Morgan Stanley debuted MSBT, its spot Bitcoin exchange-traded fund (ETF), marking the first from a major Wall Street bank. The ETF charges a 0.14% fee aimed at attracting institutional investors. Despite this, markets remain cautious; Bitcoin reaching $80,000 in April dropped from 26% to 17% YES on prediction markets the same day. This decline signals skepticism that the ETF alone will drive significant short-term price gains. Year-end Bitcoin price optimism remains modest at 5% YES, hampered by thin liquidity and broader concerns like regulatory and geopolitical challenges. Monitoring inflows into MSBT and rivals like BlackRock's IBIT will be crucial to gauge real institutional interest.

Latest article

Social Security’s $4 Million Question: Can the S&P 500 Beat a 2033 Benefits Cliff?

Social Security’s $4 Million Question: Can the S&P 500 Beat a 2033 Benefits Cliff?

30 April 2026
A retiree’s claim that Social Security payroll taxes could have grown to $4 million in the S&P 500 has renewed debate over the system’s structure. The Social Security Administration projects its main trust fund will be depleted by 2033, with incoming revenue covering 77% of benefits. The fund invests only in government securities, not stocks. The payroll tax rate is set at 12.4% of earnings up to $184,500 in 2026.
Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

30 April 2026
FatPipe shares jumped 18% to $2.92 Thursday after the company announced expanded access to its SD-WAN and cybersecurity products through public-sector procurement channels. The move follows a VeloCloud replacement program targeting customers of Arista Networks’ SD-WAN business. Trading volume reached 42.2 million shares. Investors remain cautious over execution and customer concentration risks.
Go toTop